AgomAb Therapeutics NV American Depositary Shares · AGMB

Exhibit 99.1 Agomab Announces First Patient Dosed in Global NOV-ERA Phase 2b Study of Ontunisertib in Fibrostenosing Crohn's Disease -- NOV-ERA is designed to assess the efficacy and safety of ontunisertib in approximately 320 patients with symptomatic Fibrostenosing Crohn's disease (FSCD) -- -- Global, randomized, placebo-controlled, dose-ranging study to evaluate three dose levels of ontunisertib, with endoscopic passability at Week 24 as primary endpoint -- -- Study initiation represents …

6-K · 2026-10-13 · 0001104659-26-115567

Exhibit 99.1 Agomab Reports Positive Topline Data from STENOVA Open-Label Extension Study of Ontunisertib in Fibrostenosing Crohn’s Disease -- Favorable safety and tolerability profile maintained through up to 60 weeks of treatment with ontunisertib in Fibrostenosing Crohn’s disease (FSCD) patients -- -- Low annualized FSCD-related event rate of 3%, with one endoscopic balloon dilation (EBD) and no surgeries reported over the full treatment period -- -- Radiological assessment shows trend fo…

6-K · 2026-10-01 · 0001104659-26-112564

Exhibit 99.1 Agomab Announces Positive Phase 1 Results for AGMB-447 in Patients with Idiopathic Pulmonary Fibrosis and Design of Phase 2 INSPIRIA Study -- Topline Phase 1 data shows generally favorable safety and tolerability profile of AGMB-447 -- -- Pharmacokinetic profile confirms efficient lung restriction with low systemic exposure and high exposure of AGMB-447 in the lung, in line with prior results observed in healthy participants -- -- Robust target engagement of ALK5 observed with A…

6-K · 2026-09-14 · 0001104659-26-107500

Exhibit 99.1 Agomab Announces Appointments of Marino Garcia and Dr. Naimish Patel to Board of Directors Antwerp, Belgium, September 11, 2026 - Agomab Therapeutics NV (Nasdaq: AGMB) (“Agomab” or the “Company”), a clinical-stage biopharmaceutical company focused on fibro-inflammatory diseases, today announced that shareholders approved all resolutions submitted for consideration at the Company's Special and Extraordinary General Shareholders' Meeting held on September 11, 2026. The approved re…

6-K · 2026-09-11 · 0001104659-26-107117

Exhibit 99.1 Agomab Announces Proposed Appointments of Marino Garcia and Dr. Naimish Patel to Board of Directors Antwerp, Belgium, August 10, 2026 - Agomab Therapeutics NV (Nasdaq: AGMB) (“Agomab” or the “Company”), a clinical-stage biopharmaceutical company focused on fibro-inflammatory diseases, today announced that its Board of Directors has proposed the appointments of Marino Garcia and Naimish Patel, M.D. as non-executive members of the Board of Directors. The appointments will be submit…

6-K · 2026-08-10 · 0001104659-26-093390

Exhibit 99.2 AGOMAB THERAPEUTICS NV Posthoflei 1 box 6 2600 Antwerpen (Berchem) Company number: 0674.527.310 RLE Antwerp, section Antwerp (The “Company”) Invitation to the special and extraordinary general shareholders’ meeting on September 11, 2026 Dear all, The Board of Directors of AgomAb Therapeutics NV is pleased to invite the holders of securities issued by the Company, the directors and the statutory auditor of the Company to the special and extraordinary general shareholders’ mee…

6-K · 2026-08-10 · 0001104659-26-093390